Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Coegin Pharma receivedkr7.00 Mil more from issuing new shares than it paid to buy back shares.
It receivedkr0.00 Mil from issuing more debt.
It paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedkr0.00 Mil from paying cash dividends to shareholders.
It spentkr0.01 Mil on other financial activities.
In all, Coegin Pharmaearnedkr6.99 Mil on financial activities for the
three
months ended in Mar. 2026.
Coegin Pharma (NGM:COEGIN) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Coegin Pharma's issuance of stock for the
three
months ended in Mar. 2026 was kr7.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Coegin Pharma's repurchase of stock for the
three
months ended in Mar. 2026 was kr0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Coegin Pharma's net issuance of debt for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Coegin Pharma receivedkr0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Coegin Pharma's net issuance of preferred for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Coegin Pharma paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Coegin Pharma's cash flow for dividends for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Coegin Pharma receivedkr0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Coegin Pharma's other financing for the
three
months ended in Mar. 2026 was kr-0.01 Mil.
Coegin Pharma spentkr0.01 Mil on other financial activities.
Coegin Pharma Cash Flow from Financing Related Terms
Coegin Pharma Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Coegin Pharma's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coegin Pharma Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Coegin Pharma's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr6.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of kr6.99 Mil mean?
Coegin Pharma (NGM:COEGIN) has a Cash Flow from Financing of kr6.99 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Coegin Pharma and its competitors.
Is Coegin Pharma's Cash Flow from Financing too high?
Coegin Pharma's current Cash Flow from Financing is kr6.99 Mil. Overall, Coegin Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Cash Flow from Financing compare to VRTX and REGN?
Coegin Pharma's Cash Flow from Financing of kr6.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Coegin Pharma and its competitors. Coegin Pharma's current Cash Flow from Financing is kr6.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Cash Flow from Financing of kr6.99 Mil. The current Cash Flow from Financing is kr6.99 Mil. Coegin Pharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Cash Flow from Financing is kr6.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
29GF Score
Get the complete analysis for NGM:COEGIN
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
